BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升

路透中文

Nov 13, 2025

BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升

11月13日 - ** 药物开发商Mersana Therapeutics MRSN.O的股价盘前上涨两倍多，达到28.39美元

** MRSN称Day One BiopharmaceuticalsDAWN.O 同意收购Mersana Therapeutics，交易价值可能高达2.85亿美元。

** 根据协议，Day One将向Mersana股东支付每小时25美元的预付现金- MRSN

** 如果达到某些里程碑，投资者还可获得每小时 30.25 美元的额外收益，从而使总收益达到每小时 55.25 美元 - MRSN

** 公司称交易预计将于 2026 年 1 月底完成

** MRSN 开发实验性癌症药物；Day One 专注于开发治疗儿童和成人癌症患者的药物 - MRSN

** 包括本交易日的走势在内，该股今年累计下跌约 75

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583561632"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583561632\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583561632?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-13 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583561632","market":"us","top_or_hot":-1,"title":"BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升</title></head><body><p><span>11月13日</span><span> - </span>** 药物开发商Mersana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>MRSN.O</span>的股价盘前上涨<span>两倍多，达到</span>28.39美元</p><p>** MRSN称<a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a><span><span>DAWN.O</span> </span>同意收购Mersana Therapeutics，交易价值可能高达2.85亿美元。</p><p>** 根据协议，Day One<span>将向</span>Mersana股东<span>支付</span>每小时25美元的预付现金<span>- MRSN</span></p><p>** 如果达到某些里程碑，投资者还可获得每小时 30.25 美元的额外收益，从而使总收益达到每小时 55.25 美元 - MRSN </p><p>** 公司称交易预计将于 2026 年 1 月底完成</p><p>** MRSN 开发实验性癌症药物；Day One 专注于开发治疗儿童和成人癌症患者的药物 - MRSN</p><p>** 包括本交易日的走势在内，该股今年累计下跌约 75</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-13 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升</title></head><body><p><span>11月13日</span><span> - </span>** 药物开发商Mersana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>MRSN.O</span>的股价盘前上涨<span>两倍多，达到</span>28.39美元</p><p>** MRSN称<a href=\"https://laohu8.com/S/DAWN\">Day One Biopharmaceuticals</a><span><span>DAWN.O</span> </span>同意收购Mersana Therapeutics，交易价值可能高达2.85亿美元。</p><p>** 根据协议，Day One<span>将向</span>Mersana股东<span>支付</span>每小时25美元的预付现金<span>- MRSN</span></p><p>** 如果达到某些里程碑，投资者还可获得每小时 30.25 美元的额外收益，从而使总收益达到每小时 55.25 美元 - MRSN </p><p>** 公司称交易预计将于 2026 年 1 月底完成</p><p>** MRSN 开发实验性癌症药物；Day One 专注于开发治疗儿童和成人癌症患者的药物 - MRSN</p><p>** 包括本交易日的走势在内，该股今年累计下跌约 75</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4T3WP0SW:1","article_id":"2583561632","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583561632","pubTimestamp":1763033489,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4539":"次新股","DAWN":"Day One Biopharmaceuticals Inc.","BK4563":"昨日强势股","BK4139":"生物科技","MRSN":"Mersana Therapeutics Inc."},"translate_title":"BUZZ-Mersana Soars on Day One's $285M Acquisition Deal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRSN":0.9,"DAWN":0.9},"content_text":"BUZZ-Mersana 因 Day One 2.85 亿美元的收购交易而飙升11月13日 - ** 药物开发商Mersana Therapeutics MRSN.O的股价盘前上涨两倍多，达到28.39美元** MRSN称Day One BiopharmaceuticalsDAWN.O 同意收购Mersana Therapeutics，交易价值可能高达2.85亿美元。** 根据协议，Day One将向Mersana股东支付每小时25美元的预付现金- MRSN** 如果达到某些里程碑，投资者还可获得每小时 30.25 美元的额外收益，从而使总收益达到每小时 55.25 美元 - MRSN ** 公司称交易预计将于 2026 年 1 月底完成** MRSN 开发实验性癌症药物；Day One 专注于开发治疗儿童和成人癌症患者的药物 - MRSN** 包括本交易日的走势在内，该股今年累计下跌约 75(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}